Clinical Study
The Incremental Prognostic Value of Baseline 18F-FDG PET/CT Imaging in Angioimmunoblastic T-Cell Lymphoma
Table 1
Patients’ outcome and related clinical data.
| | Case (%) | Median OS (month) | |
| | Gender | | | 0.291 | | Male | 14 (60.87%) | 49 | | | Female | 9 (39.13%) | 15 | | | Age (years) | | | 0.844 | | ≥60 | 16 (69.57%) | 28 | | | <60 | 7 (30.43%) | 23 | | | B symptom | | | 0.056 | | Yes | 13 (56.52%) | 19 | | | No | 10 (43.48%) | 49 | | | ECOG score | | | 0.012 | | ≤1 | 18 (78.26%) | 49 | | | >1 | 5 (21.74%) | 10 | | | Ann Arbor stage | | | 0.071 | | I~II | 3 (13.04%) | 42 | | | III~IV | 20 (86.96%) | 15.5 | | | IPI score | | | 0.400 | | 0~2 | 11 (47.83%) | 49 | | | 3~5 | 12 (52.17%) | 23 | | | LDH (U/L) | | | 0.579 | | Abnormal (>250) | 18 (78.26%) | 23 | | | Normal (≤250) | 5 (21.74%) | 19 | | | Albumin (g/L) | | | 0.218 | | Abnormal (<40) | 17 (73.91%) | 19 | | | Normal (40-55) | 6 (26.09%) | 49 | | | β2-MG(0.9~2.3 mg/L) | | | 0.650 | | Abnormal (>2.3) | 18 (78.26%) | 23 | | | Normal | 5 (21.74%) | 42 | | | Serous cavity effusion | | | 0.026 | | Yes | 8 (34.78%) | 10 | | | No | 15 (65.22%) | 49 | | | Ki-67 | | | 0.028 | | ≥45% | 15 (65.22%) | 19 | | | <45% | 8 (34.78%) | 28 | | | SUVmax of infiltrated lymph nodes | | | 0.202 | | ≥7.85 | 18 (78.26%) | 19 | | | <7.85 | 5 (21.74%) | 23 | | | SUVmax of extranodal lesions | | | 0.016 | | ≥4.1 | 12 (70.59%) | 15 | | | <4.1 | 5 (29.41%) | 49 | | | Extranodal involvement | | | 0.021 | | ≤1 | 14 (60.87%) | 49 | | | >1 | 9 (39.13%) | 16 | |
|
|
LDH: lactate dehydrogenase; CRP: C-reactive protein; β2-MG: beta 2-microglobulin; IPI: international prognostic index; ECOG: Eastern Cooperative Oncology Group; OS: overall survival; SUV max: the maximum standardized uptake values. Compared within groups: . |
